Comparative Analysis Of Epalrestat Tablets And Valsartan Capsules On Serum Hcy And CysC In Patients With Type 2 Diabetic Nephropathy(Phase ?)

Objective: To explore the comparative analysis of epalrestat tablets and valsartan capsules on serum homocysteine(Hcy)and cystatin C(CysC)in patients with diabetic nephropathy ?,To provide evidence-based medical evidence for the treatment of diabetic nephropathy.Materials and Methods: The concentrations of Hcy and CysC in group A before treatment were(13.93±2.12)umol/L and(0.93±0.44)mg/L,respectively.After treatment,they were(10.08±1.66)umol/L and(0.61±0.22)mg/L,respectively.The concentrations of Hcy and CysC in group B before treatment were(14.07±1.82)umol/L and(1.02±0.35)mg/L,After treatment,the concentrations of Hcy and CysC were(11.03±1.85)umol/L and(0.88±0.25)mg/L.Conclusion: Epalrestat and valsartan can reduce serum Hcy and CysC levels in patients with diabetic nephropathy stage ?,Laboratory data showed that epalrestat was more likely than valsartan to reduce plasma Hcy and CysC levels in patients with diabetic nephropathy stage ?.